63 results about "Lactic dehydrogenase" patented technology

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The invention discloses a lactic dehydrogenase LdLDH mutant and application thereof, a wild type LdLDH enzyme derived from Lactobacillus delbrueckii subsp. Bulgaricus is taken as a research object, the amino acid sequence of the wild type LdLDH enzyme is designed and modified to obtain a mutant protein, the mutant protein is named as LdLDH-M, the amino acid sequence of the mutant protein is shown as SEQ ID NO.2, the Tm value of the LdLDH-M is 77.1 DEG C, the Tm value of the LdLDH-M is 77.1 DEG C, and the Tm value of the LdLDH-M is 77.1 DEG C; compared with the wild type LdLDH enzyme, the Tm value of the LdLDH enzyme is increased by 27.4 DEG C, and the enzyme activity of the LdLDH enzyme is increased by 1.4 times. Therefore, compared with the wild type LdLDH enzyme, the LdLDH-M has remarkably improved thermal stability and enzymatic activity, and is more beneficial to widening the application range of the LdLDH-M in the fields of high-temperature biological research, industrial biological catalysis and the like.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The invention discloses an application of sodium oxamate in preparation of anti-influenza virus products, and provides an application of sodium oxamate as a lactic dehydrogenase A inhibitor in preparation of anti-influenza virus products, the sodium oxamate has broad-spectrum antiviral activity, and can play a unique action mechanism by regulating host cell metabolism (such as protein lactylation). And a new direction is provided for overcoming virus resistance.

The invention discloses a genetically engineered bacterium for synthesizing N-acetyl blue as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium is prepared by knocking out a lactic dehydrogenase gene ldh and inserting a phosphoketolase gene xfpK on a knockout site, knocking out a pyruvate oxidase gene poxB and inserting a phosphate transacetylase gene pta on a knockout site of a microorganism for producing N-acetyl blue, and knocking out an aconitase inhibition factor gene acnR, inserting a glutamate dehydrogenase gene gdhA on a knockout site, knocking out a glutamine synthetase adenylation transferase gene glnE, and inserting an alpha-ketoglutarate dehydrogenase inhibition factor gene odhI on a knockout site to obtain the strain. According to the method, the supply of the precursor acetyl coenzyme A is enhanced by introducing a non-oxidative glycolysis pathway, the pH dynamic regulation system balances the metabolic flux, and the double breakthrough of the yield and the carbon recovery rate of the N-acetyl blue is realized by combining a two-stage fermentation process.

The invention discloses a method for detecting the concentration of acetic acid in an anaerobic fermentation system by using a bioelectrochemical sensor, acetic acid is detected by using the bioelectrochemical sensor, the bioelectrochemical sensor comprises a screen-printed electrode, and the working surface of the screen-printed electrode is modified with reduced graphene oxide and polymethylene blue. The working surface of the screen printing electrode is connected with acetokinase, pyruvate kinase and lactic dehydrogenase through a cross-linking agent. According to the method, the adopted sensor has better conductivity, higher response speed and higher current intensity, when the sensor is used for detecting the concentration of acetic acid in a fermentation system, the sensor has the advantages of being easy to operate, low in sample consumption, low in price, high in accurate measurement precision, high in detection speed and the like, and rapid detection of the concentration of acetic acid can be achieved; the acetic acid concentration in the anaerobic fermentation process in different periods can be timely and accurately obtained, effective data can be provided for anaerobic fermentation analysis, and the method has important significance for monitoring the process stability of anaerobic fermentation.

The invention discloses an image processing method and device for judging suspension red blood cell hemolysis. The method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactic dehydrogenase concentration and globin concentration; utilizing the blood image set and the blood parameter information set to construct a blood hemolysis composite detection model; based on the blood hemolysis composite detection model, processing the collected blood image and blood parameters to obtain hemolysis detection result information; the hemolysis detection result information is used for representing erythrocyte hemolysis information of the blood corresponding to the collected blood image and blood parameters.

The application discloses genetically engineered bacteria for producing alpha-ketoglutaric acid and application. The genetically engineered bacteria are obtained by weakening the expression of alpha-ketoglutaric acid dehydrogenase gene odhA, weakening the expression of glutamate transporter protein gene cg1434, weakening the expression of glutamate synthase key subunit gene gltB, weakening the expression of lactic acid dehydrogenase gene ldh, weakening the expression of glutamate dehydrogenase gene gdh, weakening the expression of serine / threonine protein kinase gene pknG, enhancing the expression of pyruvate carboxylase gene pyc, introducing and expressing glutamate oxidase gene lgox at the site of lactic acid dehydrogenase ldh gene, and enhancing the expression of strong catalase gene katA on the basis of a Corynebacterium glutamicum starting strain. The genetically engineered bacteria can efficiently produce alpha-ketoglutaric acid under the condition of limited ammonia culture, and have a good application prospect.

This invention discloses the use of polylactic acid (PLA) and its copolymers in the preparation of products that promote hair follicle growth and repair, belonging to the field of biomedical technology. Through in vitro and in vivo experiments, this invention demonstrates that PLA can significantly upregulate the expression of lactate dehydrogenase A and transforming growth factor β2 in dermal papilla cells, promoting dermal papilla cell proliferation and hair follicle growth and damage repair. Based on these findings, this invention provides the application of PLA and its copolymers in the preparation of products that promote hair follicle growth and damage repair, offering a safe and effective treatment strategy for hair follicle-related diseases.

The invention discloses issatchenkia orientalis capable of efficiently synthesizing L-malic acid and application of the issatchenkia orientalis, and belongs to the technical field of biological engineering. In an existing gene edited yeast strain in a laboratory, endogenous lactic dehydrogenase IoLDH2 and IoLDH3 are over-expressed, endogenous IoLDH1 is knocked out, and lactic dehydrogenase EcD-LDH from escherichia coli and lactic dehydrogenase NmD-LDH from neisseria meningitidis are over-expressed. After fermentation for 72 h in a 5 L fermentation tank, the accumulation amount of L-malic acid reaches 296.27 g / L, the yield is 0.97 g / g, the production intensity is 4.11 g / L / h, and the by-product lactic acid is remarkably reduced from 23.56 g / L to 6.7 g / L and is reduced by 71.56%.

The invention belongs to the field of medicines, and relates to a scutellarin aglycone derivative as well as a preparation method and application thereof. The scutellarin aglycone derivative has a structure as shown in a formula I. The preparation method comprises the following steps: reacting scutellarin (a compound II) with methanol to obtain a compound III, then reacting with bornyl chloroacetate (a compound IV) to obtain a compound V, and finally carrying out an alkaline hydrolysis reaction to obtain the compound I, the scutellarin aglycone derivative has the effect of preventing or treating cardiovascular and cerebrovascular related diseases, can improve the activity of superoxide dismutase (SOD), inhibit the production of lactic dehydrogenase (LDH) and reduce the malondialdehyde (MDA) level superior to that of scutellarin, has the inhibiting effect on inflammatory factors TNF-alpha, IL-6 and IL-1beta in cell supernatant superior to that of scutellarin, and can be used for preparing a medicine for treating cardiovascular and cerebrovascular related diseases, such as cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases and cardiovascular and cerebrovascular related diseases. The invention has the potential of preparing or preventing cardiovascular and cerebrovascular related diseases.

The invention belongs to the technical field of bioinformatics and medical detection, and particularly relates to a marker combination for neuroblastoma (NB) noninvasive risk level grading, a prediction model, a prediction method and application thereof. The marker combination is used for determining the sex, determining whether the month age is greater than 18 months, determining whether plasma MYCN is amplified, determining whether tumors are metastatic, and determining the content of neuron-specific enolase and lactic dehydrogenase; a machine learning algorithm is used for constructing an NB noninvasive risk degree grading prediction model, the comprehensive performance of the random forest model is optimal, the area value under a subject working characteristic curve reaches 0.956, the sensitivity is 92.9%, the specificity is 82.1%, the accuracy rate is 87.5%, the Kappa value is 0.75, the F1 score is 0.881, and NB middle and low risk patients and NB high risk patients can be effectively distinguished; the NB non-invasive risk level grading prediction model constructed by the invention can quickly, accurately and non-invasively perform NB risk level grading, and has a relatively good clinical application value.

The invention discloses a pharmaceutical composition for preventing and treating inflammatory bowel disease as well as a preparation method and application thereof, and relates to the technical field of modernization of traditional Chinese medicines. The pharmaceutical composition comprises the following active ingredients in parts by weight: 5-30 parts of turmeric, 4-30 parts of green tea, 3-20 parts of liquorice, 5-30 parts of poria cocos and 2-20 parts of cinnamon. The pharmaceutical composition acts on inflammatory factors such as TNF-alpha, IL-1beta and IL-6 by adjusting key signal channels such as NF-kappa B and IL-17, plays a remarkable anti-inflammatory role, has ABTS free radical scavenging and iron ion reducing capabilities, effectively relieves oxidative stress injury caused by inflammation, can remarkably inhibit release of LPS-induced lactic dehydrogenase, and has a remarkable anti-inflammatory effect on inflammatory factors such as TNF-alpha, IL-1beta and IL-6. And the mRNA expression level of the proinflammatory factor is reduced. The invention provides a solid experimental basis and a wide application prospect for developing a safe and efficient inflammatory bowel disease treatment medicine with a clear mechanism.

The invention discloses an L-lactic dehydrogenase A mutant MALDHAK248A with reduced enzyme activity and an application of the L-lactic dehydrogenase A mutant MALDHAK248A. The mutant MALDHAK248A of the L-lactic dehydrogenase A has an amino acid sequence as shown in SEQ ID NO.3. The invention also discloses a preparation method of the mutant MALDHAK248A. The invention provides a mutant MALDHAK248A of L-lactic dehydrogenase A. The amino acid sequence of the mutant MALDHAK248A is as shown in SEQ ID NO.3. The mutant MALDHAK248A can be used for preparing L-lactic dehydrogenase A. The invention further provides a preparation method of the mutant MALDHAK248A. According to the mutant MALDHAK248A, site-specific mutagenesis is carried out on an amino acid sequence as shown in SEQ ID NO.2, Lys at the 248th site is mutated into Ala, so that the activity of the L-lactic dehydrogenase A is reduced, and the enzyme activity of the L-lactic dehydrogenase A is reduced by 31%. The L-lactic dehydrogenase A mutant MALDHAK248A obtained by the invention can be used as a mutant material capable of remarkably reducing the catalytic activity of an enzyme, and provides reference for further research on the functions of the L-lactic dehydrogenase A.

The invention provides a lactic acid bacteria genetic engineering strain for producing malic acid as well as a construction method and application thereof, and belongs to the technical field of genetic engineering and microbial fermentation. The lactic acid bacterium gene engineering strain is a lactic acid bacterium gene engineering strain with two lactic dehydrogenase genes and one cluster protein gene being knocked out; the two lactic dehydrogenases are respectively a lactic dehydrogenase LCAZH0554 and a lactic dehydrogenase LCAZH2512, and the clusterin is a clusterin containing genes of LCAZH2364, LCAZH2365, LCAZH2366 and LCAZH2367. The invention further discloses a preparation method of the clusterin. Three target knockout plasmids are sequentially transferred on the basis of an original lactic acid bacterium strain for gene knockout, the lactic acid bacterium gene engineering strain is finally obtained, and the malic acid yield is obviously increased compared with that of the original strain when the lactic acid bacterium gene engineering strain is adopted for fermentation.

The invention relates to the field of biological medicine, in particular to a lactic dehydrogenase LDHB protein 196-site serine phosphorylation antibody as well as a preparation method and application thereof. On the basis of the 196-site serine phosphorylated polypeptide of the lactic dehydrogenase LDHB protein, the 196-site serine phosphorylated antigen and antibody of the lactic dehydrogenase LDHB protein are prepared, and a preparation method of the 196-site serine phosphorylated antibody of the lactic dehydrogenase LDHB protein is provided. The prepared lactic dehydrogenase LDHB protein 196-site serine phosphorylated antibody can be used for detecting low-abundance LDHB Ser196 signals, is suitable for various detection platforms such as Western blot and immunohistochemistry, and meets the detection requirements of tumor tissue samples.

The invention discloses a small-molecule inhibitor based on lactic dehydrogenase targeted design and application thereof, and belongs to the field of biological medicine, the small-molecule inhibitor is a benzenesulfonamide compound or pharmaceutically acceptable salt thereof, and the structure of the small-molecule inhibitor is shown in the specification. The lactic dehydrogenase inhibitor is suitable for treating and / or preventing diseases mediated by lactic dehydrogenase.

The invention relates to the fields of gene engineering, enzyme engineering and bioinformatics, and particularly discloses application of glycine free radical enzyme in preparation of propylene glycol. Transforming a glycolytic pathway of escherichia coli: knocking out phosphofructokinase, acetaldehyde dehydrogenase, lactic dehydrogenase and ethanol dehydrogenase of the strain; according to the present invention, the following genes driven by the strong promoter, such as glycerol dehydrogenase, fructose-6-phosphate aldolase, mannitol-1-phosphate dehydrogenase, and dihydroxyacetone kinase, glycine free radical enzyme and free radical activating enzyme of citrobacter freundii, are integrated in the genome so as to enhance the metabolic pathway for synthesizing 1, 2-propylene glycol, and finally obtain the genetically engineered bacterium, wherein the genes comprise glycerol dehydrogenase, fructose-6-phosphate aldolase, mannitol-1-phosphate dehydrogenase, dihydroxyacetone kinase, glycine free radical enzyme and free radical activating enzyme of citrobacter freundii. The R-1, 2-propylene glycol produced by using the genetically engineered bacterium through a biological method can be applied to the fields of medicines, cosmetics, foods and the like, and high-added-value products are developed to meet the requirements of different fields on the R-1, 2-propylene glycol.

The invention discloses a stable lactic dehydrogenase and uric acid combined detection kit with strong anti-interference capability, and belongs to the technical field of detection. The joint detection kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 contains a buffer solution, a composite anti-interference agent, a composite stabilizer, L-lithium lactate, a compound surfactant, 4-aminoantipyrine, peroxidase and a preservative diazolidinyl urea; the reagent R2 contains a buffer solution, a coenzyme (NAD < + >), N-ethyl-N-(3-sulfopropyl)-3-methylaniline sodium salt uricase, a compound stabilizer, a compound surfactant and a preservative epsilon-polylysine hydrochloride. According to the present invention, the lactic dehydrogenase detection and the uric acid detection can be simultaneously achieved by one reagent, such that the use convenience is substantially improved, and the stability and the anti-interference ability of the reagent are further improved. The reagent disclosed by the invention is simple, convenient and rapid to operate, is suitable for automatic analysis, and is a lactic dehydrogenase and uric acid combined detection reagent which is more stable and strong in anti-interference capability.

The application discloses a kind of compound enzyme and its application, belong to the field of biotechnology.The compound enzyme provided by the application includes: pectinase 5-15 parts by weight, glucose glycosidase 5-15 parts, glycerol 2-8 parts and water 15-20 parts, the compound enzyme also includes phytase 2-6 parts, lactic acid dehydrogenase 1-4 parts.The compound enzyme provided by the application can significantly improve the extraction rate of soybean isoflavones, and the content of isoflavones is significantly improved.

The invention discloses a construction method and application of an engineering bacterium for increasing the yield of alpha-ketoglutaric acid. Wild E.coli.W3110 serves as a chassis strain, lactic dehydrogenase ldhA, pyruvate dehydrogenase poxB and formic acid C-acetyltransferase pflB are knocked out firstly, and the flow direction of pyruvic acid to lactic acid, acetic acid and formic acid is blocked; meanwhile, the promoter PBBaJ23109 is used for replacing a natural promoter of the sucA gene, so that alpha-ketoglutaric acid dehydrogenase is weakened, and the decomposition way of alpha-ketoglutaric acid is weakened; the phosphoenolpyruvate carboxylase ppc is overexpressed, and the flow direction of phosphoenolpyruvate to oxaloacetic acid is enhanced; isocitrate dehydrogenase icd from escherichia coli is overexpressed, so that synthesis of a product is promoted; besides, pyruvate dehydrogenase derived from saccharomyces cerevisiae is introduced and coded by genes PDB1, PDA1 and LAT1, so that an important precursor, namely pyruvic acid, is promoted to flow to acetyl coenzyme A; the engineering strain with high yield of alpha-ketoglutaric acid is finally obtained, the yield of 75.1 g / L can be achieved in a 5L fermentation tank through a fed-batch fermentation method for 40 hours, and the conversion rate is 39.6%.

The invention belongs to the technical field of aquatic immunity and biological preparations, and discloses a CXCL20a protein mutant and application of the CXCL20a protein mutant as a grass carp reovirus inactivated vaccine adjuvant. In order to improve the immunomodulatory activity of CXCL20a, the applicant constructs and obtains a CXCL20a mutant protein. After the mutant and a GCRV-II type inactivated vaccine are combined to immunize grass carp, the expression of immune related genes can be remarkably promoted, the activity of serum acid phosphatase and superoxide dismutase is enhanced, and meanwhile, the level of lactic dehydrogenase is reduced. A challenge experiment proves that the survival rate of the grass carp combined with the inactivated vaccine for immunization is increased by about 8% compared with that of a non-mutant combined group, and the in-vivo virus load is reduced. As an immunologic adjuvant, the CXCL20a mutant M-C20 provided by the invention can effectively enhance early immune response and overall protection effect in vaccine immunity, and has good safety, stability and application prospect.

The invention discloses a construction method and application of escherichia coli genetically engineered bacteria for producing malic acid by synergistically utilizing CO2, and belongs to the technical field of bioengineering. According to the invention, an L-malic acid chassis strain MG1655W (DE3) constructed by a gene editing technology in a laboratory is used as an initial strain, a lactic dehydrogenase encoding gene ldhA and a phosphate acetyltransferase encoding gene pta in escherichia coli are knocked out on the basis, the production paths of lactic acid and formic acid are blocked, and the yield of lactic acid and formic acid is increased. The method comprises the following steps of: firstly, amplifying a phosphoenolpyruvate carboxylase gene ppc and a CO2 transporter gene CA, constructing a recombinant plasmid, introducing the recombinant plasmid pACYCDuet-1-CA-ppc into an expression host MG1655W (DE3) delta ldhA delta pta, and screening to obtain the engineering bacterium MG1655W (DE3) delta ldhA delta pta-CA-ppc by overexpressing the ppc gene and the CA gene and improving the CO2 immobilization and concentration capability of escherichia coli. The obtained engineering bacterium is subjected to cell proliferation under an aerobic condition and malic acid accumulation under an oxygen limiting condition, the final malic acid yield is increased to 140-212%, and the engineering bacterium has important industrial application value.

This invention discloses the application of lily-derived nanovesicles (LDPNVs) as a novel radiation protection drug in radiation-induced lung injury, relating to the field of biomedical technology. It includes administering effective doses of lily-derived nanovesicles to subjects to prevent and alleviate radiation-induced lung injury. The LDPNVs can improve the viability and clonal survival rate of radiation-damaged lung epithelial cells at the cellular level, and alleviate pathological damage to lung tissue and improve lung function at the animal level. This invention achieves the blocking of core pathways of radiation injury, specifically downregulating the expression of key inflammatory factors, reducing lactate dehydrogenase release and total protein content in bronchoalveolar lavage fluid, and correcting abnormal respiratory rate and ventilatory dysfunction. It yields a novel radiation protection drug for radiation-induced lung injury that is naturally derived, stable in preparation, highly targeted, and has a definite protective effect, filling the application gap of plant-derived nanovesicles in this field and providing a safe and effective intervention for complications of radiotherapy for thoracic tumors.

The invention discloses a lactococcus lactis recombinant bacterium for expressing cyclic diadenylate and application of the lactococcus lactis recombinant bacterium. The recombinant bacterium is obtained by carrying out multi-gene synergistic modification on lactococcus lactis. The method specifically comprises the following steps: carrying a homologous diadenylate cyclase (DAC) gene, overexpressing glycolysis key enzyme phosphofructokinase (PFK), knocking out a phosphodiesterase (PDE) gene for degrading c-di-AMP, and knocking out a lactic dehydrogenase (ldh) gene. Through the synergistic effect of the transformation, the supply of the precursor ATP is remarkably improved, and the degradation of the c-di-AMP and the accumulation of lactic acid byproducts are reduced, so that the efficient expression of the c-di-AMP is realized.

This invention provides the use of Cm-CATH2 in the preparation of drugs for treating silicosis, belonging to the field of biomedical technology. This invention provides the application of Cm-CATH2 and / or pharmaceutically acceptable salts of Cm-CATH2 in the preparation of drugs for treating silicosis, and verifies the therapeutic effect of Cm-CATH2 on silicosis animal models by constructing such models. The results show that Cm-CATH2 can act on silicosis at multiple targets after the early stage of silicosis in animal models. It reduces oxidative stress levels by downregulating lactate dehydrogenase (LDH), downregulates matrix metalloproteinase 2 (MMP2) and extracellular matrix glycosaminoglycans (GAG), and ultimately reduces collagen III (COL-III) levels, thereby achieving an anti-fibrotic effect. This multi-target approach can effectively alleviate fibrosis progression. Therefore, Cm-CATH2 can be used to treat silicosis, and a dose-response effect exists, with good efficacy at high doses.

The invention belongs to the technical field of genetic engineering, and particularly relates to an acetoin-producing lactic acid bacteria engineering bacterium, a construction method and application. The invention provides a lactobacillus engineering bacterium for producing acetoin. The basic bacterium of the lactobacillus engineering bacterium is lactobacillus casei; a lactic dehydrogenase gene 1 and a lactic dehydrogenase gene 2 are knocked out from a genome of the lactobacillus casei. The lactobacillus casei is taken as a basic bacterium, has the characteristics of GRAS safety, acid resistance and direct application potential in a food system, and can be used for flavor improvement, probiotic metabolism and postbiotic development. According to the invention, key lactic acid metabolic enzyme genes in lactobacillus casei are knocked out, an acetoin generation pathway is enhanced, acetoin can be stably and efficiently produced, and the engineering bacterium has good metabolic stability in a fermentation system and can be widely applied to the fields of food fermentation, natural perfume production and the like.